Do emerging markets, including India, have anything to worry about in case the US Federal Reserve hikes rates and the upcoming Brexit vote?
The recent US jobs report has eased fears of a hike in the Fed meeting. However, chair Janet Yellen has indicated a hike looks inevitable this year. This will reverse the dollar's weakening that has driven the global equity market rally since February. Hence, a correction in markets globally is likely due to the Fed hike, and emerging markets, including India, will be no exception.
At the same time, we think the Fed hike will be measured and, hence, will provide a pullback that will give investors a better entry point. Brexit is a bigger threat for the market. An actual Brexit could lead to a sharp correction, though the market is still treating it as a low probability event.
Indian markets seem to be building into many positives right now. How sharp can the correction be, if any?
We think the bigger threat to the markets is a global correction, rather than something led by India-specific factors. Within India, a poor monsoon could raise fears of a rise in inflation, especially at a time when global commodity prices are rallying. I think with the (goods and services tax) GST, it is now getting to a question of 'when' rather than 'if'. So, even if GST does not get passed in the (coming) session (of Parliament), the market expectation will be that it gets done in the next one.
What is your analysis of the March quarter results?
These were a positive surprise. After many quarters, we saw the number of companies beating analyst estimates at nearly 40 per cent exceed those missing the estimates (35 per cent). The aggregate numbers, of course, disappointed due to the high provisioning (for stressed loans) at banks. But, the net profit for Sensex companies (ex-banks) grew at 15 per cent. There is a greater comfort to our expectation of a 12-14 per cent earnings growth in FY17, the best in five years.
Which sectors are you overweight and underweight on?
We are overweight the domestic consumer plays, both in rural and urban consumption. We especially like automobiles and rural-based stocks like agro chemicals. We also like select stocks in the roads, railways and defence spaces. We are underweight on telecom and the materials sector.
Is the low commodity price era over for now? What is the outlook for capital goods, automobile and metal stocks in this backdrop?
It is important to put this in perspective. Commodity prices have seen a sharp drop over 18 months and rallied from the lows. But, they are still significantly lower than 18 months ago. So, the super-cycle in commodities is clearly over and average prices over the next five years will be lower than they were over the past five years.
The investment part of the Chinese growth story is in a structural slowdown. We would, therefore, not be long-term buyers of metal stocks, though we play cyclical rallies, led by beaten-down valuations and imposition of MIP (minimum import price).
While commodity prices do help margins of sectors like automobiles and capital goods, demand and volume are more critical stock price drivers. We are positive on automobiles, as we see a demand recovery led by the pay commission, a better monsoon, leading to revival in rural demand, and falling interest rates. We are, however, cautious on the capital goods sector, especially in power, since the revival in investment demand is still 12-18 months away.
The markets seem to be liking niche plays like Thyrocare, Dr Lal PathLabs, Ujjivan Financial Services and Equitas Holdings. What is your view for these players in terms of earnings growth potential?
The health care sector, as well as the micro finance companies going into small banks, are both interesting spaces from a long-term perspective and will show strong earnings growth. Some companies in the health care sector are not cheap and will need to execute perfectly to sustain valuations. Micro finance companies are great long-term plays, but face challenges in the near term as they transform to a small bank. These include the costs of building a liability franchise and, of course, providing for CRR (cash reserve ratio) and SLR (statutory liquidity ratio). That apart, it would entail a change in the culture of the organisation as they evolve into a multi-speciality finance entity.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)